Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial

作     者：Simon J Bowman 

作者机构：Rheumatology Department University Hospitals Birmingham NHS Foundation Trust Birmingham UK Institute of Inflammation and Ageing College of Medical and Dental Sciences University of Birmingham UK National Institute for Health Research Birmingham Biomedical Research Centre University of Birmingham Birmingham UK Rheumatology Department Milton Keynes University Hospital Milton Keynes UK Rheumatology Clinic Scripps Memorial Hospital and Research Institute La Jolla CA USA Department of Medicine Rheumatology and Clinical Immunology Charité Universitätsmedizin and Deutsches Rheumaforschungszentrum Berlin Germany Université Paris Saclay Assistance Publique-Hôpitaux de Paris Hôpital Bicêtre INSERM U1184 Le Kremlin Bicêtre France Division of Oral Medicine Tufts School of Dental Medicine Boston MA USA Division of Rheumatology Johns Hopkins School of Medicine Baltimore MD USA Chronic Diseases Research Center Nova Medical School Lisbon Portugal Instituto Português de Reumatologia Lisbon Portugal Rheumatology Department Hospital Cuf Descobertas Lisbon Portugal Clinic of Rheumatology University Hospital Santa Maria della Misericordia Department of Medical Area University of Udine Udine Italy Division of Rheumatology and Clinical Immunology Department of Internal Medicine IV Ludwig-Maximilians-University of Munich Munich Germany Department of Rheumatology Liverpool University Hospitals NHS Foundation Trust and Edge Hill University Liverpool UK Novartis Pharma Basel Switzerland Novartis Pharmaceuticals East Hanover NJ USA 

出 版 物：《四川生理科学杂志》 (Sichuan Journal of Physiological Sciences)

年 卷 期：2021年第43卷第10期

页      面：1799-1799页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Novartis Novartis Pharmaceuticals Corporation, NPC Sociedad Española de Reumatología, SER 

主　　题：subcutaneous patients doses 

摘      要：Background:Sjögren s syndrome is an autoimmune disease characterised by dry eyes and mouth,systemic features,and reduced quality of *** are no disease-modifying treatments.A new biologic,ianalumab(VAY736),with two modes of suppressing B cells,has previously shown preliminary *** dose-finding trial aimed to assess the safety and efficacy of different subcutaneous doses of ianalumab in patients with moderate to severe primary Sjögren s syndrome.